Imodium N6 (Loperamide Hydrochloride)

Loperamide hydrochloride acts as a peripheral μ‑opioid receptor agonist in the gut. By binding to these receptors it slows intestinal motility, enhances water and electrolyte absorption, and decreases the volume of stool, thereby alleviating diarrhea without affecting the central nervous system.

The appropriate dose of Imodium N6 is determined by a qualified healthcare professional based on the patient’s age, weight, severity of symptoms, and clinical response. Prescribers follow local labeling guidelines and adjust the regimen as needed.

Safety data for loperamide hydrochloride in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against possible risks before prescribing Imodium N6 to pregnant or nursing individuals, and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Imodium N6 product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Imodium N6 (loperamide) is a peripheral opioid agonist that primarily slows gut motility, whereas other agents such as bismuth subsalicylate act by coating the mucosa and reducing inflammation. Loperamide generally provides rapid symptom control but requires caution in patients with certain infections or cardiac risk factors.

Imodium N6 should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat, and direct sunlight to maintain product stability throughout its shelf life.

Imodium N6 is taken orally, usually with a glass of water. The tablet is swallowed whole and should be used according to the prescriber’s instructions, which may include an initial dose followed by maintenance doses based on symptom control.

Serious risks include severe constipation leading to bowel obstruction, toxic megacolon in patients with underlying inflammatory bowel disease, and cardiac arrhythmias such as QT prolongation, especially when combined with other QT‑prolonging drugs or CYP3A4 inhibitors.

Imodium N6 is contraindicated in children under two years of age, individuals with known hypersensitivity to loperamide, patients with acute dysentery, ulcerative colitis, or bacterial enterocolitis, and those taking strong CYP3A4 inhibitors without medical supervision.